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Most HIV-1 isolates depend on CCR5 or CXCR4 to infect target cells, and efficient use of other coreceptors is rare. We cloned HIV-1
envelopes from virus at acute infection and found that most use CCR3 efficiently. This result contradicts prevailing data, suggesting that CCR3
usage is rare. We hypothesized that direct isolation into PBMC biases selection of viruses that use CCR5 and not CCR3. We therefore compared
coreceptor use of isolates obtained by PBMC coculture with envelopes cloned directly from patient blood samples, which should represent
actively replicating species. Viruses derived by cloning generally used CCR3 and CCR5 with equally efficiently. In contrast, we found that viruses
isolated by PBMC coculture largely, or exclusively, used CCR5. Regardless of whether CCR3 use contributes to HIV-1 transmission or
pathogenesis, our results demonstrate that ‘primary isolates’ generated by PBMC culture are unlikely to accurately represent the in vivo replicating
quasi-species.
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CD4 and a chemokine coreceptor, usually CCR5 or
CXCR4, mediate binding, membrane fusion and cellular
uptake of human immunodeficiency virus (HIV)-1 and -2
(Clapham and McKnight, 2001). Viruses that use CCR5 (R5
phenotype) are present throughout the course of infection
(Bjorndal et al., 1997; de Roda Husman et al., 1999; Fiore et
al., 1994; Jansson et al., 1999; Long et al., 2002; McNearney
et al., 1992). Viruses that additionally (R5X4 phenotype), or
exclusively (X4 phenotype), use CXCR4 evolve during
disease progression in about 50% of cases (Fiore et al.,
1999; Karlsson et al., 2003; Scarlatti et al., 1997; Shankar-
appa et al., 1998). For HIV-1, other coreceptors such as
CCR2b, CCR3, CCR8, CXCR6 and GPR15 have been shown
to be used in vitro, albeit to much lower levels (Choe et al.,
1996; Deng et al., 1997; Farzan et al., 1997; Rucker et al.,⁎ Corresponding author. Fax: +44 20 7679 9555.
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doi:10.1016/j.virol.2006.04.0021997; Vodros et al., 2001). Broader and more efficient use of
alternative coreceptors has been shown for HIV-2 (Clapham
and McKnight, 2002; Deng et al., 1997; McKnight et al.,
1998; Morner et al., 1999).
The relevance of infection mediated via ‘minor’ coreceptors
is unclear, and it is generally thought that only CCR5 and
CXCR4 play a significant role in vivo (Moore et al., 2004).
However, CCR3 use has been implicated in microglial infection
with a potential link to neuropathogenesis (Gabuzda et al., 1998;
He et al., 1997). The prototype central nervous system (CNS)-
derived viruses, HIV-1YU2 and HIV-1JRFL, use CCR3 efficiently
(Choe et al., 1996; He et al., 1997). However, we and others
reported that CCR3 use may not be confined to brain derived
viruses but may be a common feature in late or chronic infection
(Dittmar et al., 1997; Ohagen et al., 2003; Peters et al., 2004).
Here, we show that CCR3 use, in addition to CCR5, is a
common phenotype of in vivo replicating HIV-1 viruses. We
also show that virus isolation by peripheral blood mononuclear
cells (PBMC) coculture favors the growth of CCR5 only using
strains, explaining why most “primary” HIV isolates do not use
CCR3. The results suggest that current viruses and envelopes
Table 1





Infectivity (×104 FFU/ml) for
NP2/CD4 U87/CD4
CD4 alone CCR3 CCR5 CCR8 CXCR4 APJ CD4 alone CCR1 CCR2b CCR5
MM1 1.2.1 28 0.03 67 62 0.5 0.1 – – c – – 45
1.2.3 28 – 51 87 – 0.04 0.01 – – – 69
1.2.4 28 – 0.2 1.6 – – – – – – 1.6
1.5.58 84 – 19 130 0.8 0.05 0.02 – – 0.01 150
MM2 2.5.2 32 – 350 210 10 0.1 – – – – 48
MM3 3.2.2 18 – 0.1 0.5 – – – – – – 0.3
3.4.1 30 – 70 90 2.0 0.07 – – – – 97
MM4 4.1.33 17 0.03 105 61 0.2 0.06 0.03 – – – 62
4.1.34 17 0.02 0.6 0.4 – 0.02 0.01 nd d nd nd nd
4.4.48 52 – 117 93 0.3 0.02 0.02 – – – 97
MM8 8.2.50 12 0.03 120 140 11 0.03 – – – – 71
8.2.51 12 – 15 9 0.5 0.03 – – – – 6
8.4.51 32 0.02 1.0 27 0.5 0.1 0.01 – – – 23
MM23 23.2.B 15 nd 0.02 1.6 0.07 0.07 nd nd nd nd nd
23.2.D 15 nd 2.1 9.3 0.03 0.03 nd nd nd nd nd
23.2.E 15 nd 60 76 0.5 0.5 nd nd nd nd nd
23.2.H 15 nd 16 30 0.02 0.02 nd nd nd nd nd
MM27 27.1.F 28 nd 3.5 100 0.2 0.2 nd nd nd nd nd
27.1.G 28 nd – 1.8 – – nd nd nd nd nd
27.1.J 28 nd 4.0 180 0.3 0.3 nd nd nd nd nd
27.1.K 28 nd 5.0 150 0.3 0.3 nd nd nd nd nd
MM28 28.1.5 6 nd 32 90 0.07 0.07 nd nd nd nd nd
a Full-length molecular clone containing gp120 cloned directly from uncultured patient PBMC, inserted into an HIV-1HXB2-based vector.
b Time-point from which the patient envelope was amplified, in days from onset of symptoms characteristic of primary HIV-1 infection.
c –, ≤100 FFU/ml.
d nd, not determined.
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the most relevant HIV quasi-species.
Results
We first determined the frequency of CCR3 use by HIV-1
Envs present at seroconversion. The Env surface unit (gp120)
was amplified from uncultured patient PBMC from eight
seroconverting men who presented with symptoms of acute
retroviral infection. The env sequences were inserted into an
HIV-1HxB2-based replication competent vector and sequenced
to exclude any identical env clones. Sequence analysis classed
the viral Envs as HIV-1 clade B (the env sequences have beenFig. 1. The CCR3 antagonist UCB35625 inhibits infection of NP2/CD4/CCR3 cells. I
increasing concentrations of the CCR3 antagonist UCB35625, verifying the specificit
wells.submitted to GenBank, for accession numbers see Materials and
methods). Virus was produced through 293T cells and
coreceptor use determined on the NP2 and U87 indicator cell
lines (Deng et al., 1996; Soda et al., 1999). Briefly, viruses were
titrated on cells in triplicate, and the cells were stained for p24
expression 48 h later. All patient Envs were R5 tropic and none
of them used CXCR4 efficiently (Table 1). The limited infection
of CXCR4 expressing cells detected with some high titre
viruses was more than 2-logs lower than the infection obtained
on CCR5 expressing cells, and these Envs therefore are not
classically dual tropic. More interestingly, 7/8 patients harbored
viruses with Envs that in addition to CCR5 could use also CCR3
to a substantial degree, the exception being patient MM27.nfection of NP2/CD4/CCR3 cells by the Env-chimeric viruses can be blocked by
y of the interaction. Error bars represent the standard deviation between triplicate
491M.M.I. Aasa-Chapman et al. / Virology 351 (2006) 489–496Indeed, almost half of the Envs could use CCR3 as efficient as,
or even more efficiently than, CCR5. For example, virus 1.2.1
from patient MM1 plated to 6.7 × 105 focus forming units
(FFU)/ml and 6.2 × 105 FFU/ml on CCR3 and CCR5
expressing cells, respectively.
To verify that infection was mediated through an interaction
with CCR3, we pre-incubated CCR3 expressing target cells
with the CCR3 antagonist UCB35625 (1 h at 37 °C) (Sabroe et
al., 2000). Almost 100% inhibition of the infection by viruses
from MM1 and MM4 was achieved at higher (≥100 nM)Fig. 2. CCR3 mediated infection by patient Env-chimeric viruses. The percentage of v
with patient Env gp120 derived from early (black bars) and chronic (white bars) infec
experiments.concentrations of UCB35625 (Fig. 1). Infection of CCR5
expressing cells was unaffected at the same concentrations (data
not shown).
HIV-1 envelopes from chronic infection also exhibit efficient
use of the CCR3 coreceptor
Next we determined if the frequent and efficient CCR3 use is
retained beyond seroconversion (at time-points between 316 and
833 days after onset of acute infection symptoms). To ensure thatirus titer on NP2/CD4/CCR3 cells compared to NP2/CD4/CCR5 cells, of viruses
tion time-points. The bars represent the mean ratio for at least three independent
492 M.M.I. Aasa-Chapman et al. / Virology 351 (2006) 489–496we sampled currently replicating virus, Envs from these chronic
infection time-points were cloned from patient plasma viral RNA
rather than PBMC as before. Fig. 2 shows that efficient CCR3 use
was maintained in chronic infection in all patients. Each bar
indicates the mean value for three or more independent
experiments and error bars the standard deviation between
experiments. Half (25 of 48) of all Envs characterized could
use CCR3 within 2-fold of their CCR5 use. There was no
significant difference in the level of CCR3 use, compared to
CCR5 use, between Envs cloned from acute (median 33.8%) and
chronic (median 50.0%) infection (Student's t test, P > 0.05).
Interestingly, in MM27 where very limited CCR3 use was found
in early infection, we saw gain of efficient CCR3 use with time.
Comparative experiments excludes assay artefacts
The efficient use of CCR3 throughout infection is contradic-
tory to reported frequencies (Broder and Jones-Tower, 1999).
However, the greater efficiencyofCCR3usedescribedhere is not
due toa super-sensitive indicator cell. TheefficiencyofCCR3use
for HIV-1 viruses JRFL, SF162, YU2, SL2, 89.6, 2028, 2076,
MN,NL4.3 and IIIB onNP2 cells was similar to those previously
published (Fig. 3A) and clearly much less efficient than the
majority of virus clones shown here (Fig. 2). The highest level of
CCR3 (∼30%) use was observed with HIV-1JRFL and HIV-1YU2,
which previously has been described to use CCR3 ‘efficiently’
(Choe et al., 1996; He et al., 1997). Furthermore, when we sub-
cloned the Env surface unit (gp120) from a subgroup of the
standard strains intoour recombinant virus system, containing the
trans-membrane unit (gp41) derived from HIV-1HXB2, we
observed no change in CCR3 use (Fig. 3B). Thus, we conclude
that theefficientuseofCCR3thatweobservedwithclonedEnvs is
not due to an artefact of our assay system.
Virus isolation through PBMC favors the growth of CCR5 only
using viruses
Phytohemagglutinin and interleukin-2 stimulated PBMC
are commonly used to isolate HIV in the laboratory. Only aFig. 3. Analysis of CCR3 usage by previously characterized HIV-1 viruses. (A) The
titrated on the NP2 indicator cell lines. The bars represent the mean ratio of at lea
experiments. (B) Transfer of viruses' Env surface unit into the HIV-1HxB2 vector dosmall minority of these cells express CCR3 at their cell
surface (unpublished data). In the above experiments, we
show that direct amplification from either PBMC or plasma
yields Envs that use CCR3. We reasoned that, in contrast to
direct cloning of Envs, isolation methods using PBMC
might select viruses using CCR5 only. To test this
hypothesis, we isolated viruses by PBMC coculture from
three patients (MM1, MM23 and MM27), at the same or
similar time-points as the cloned Envs (Fig. 4). Despite
MM1, MM23 and MM27 harboring “replicating” R3R5
viruses (left panel, Fig. 4), in the majority cases isolation
into PBMC culture favored loss of CCR3 use for exclusive
CCR5 use (right panel, Fig. 4). Apart for one isolate
(MM23-1), none of the PBMC isolates could efficiently use
CCR3 (range <1% to 6% of CCR5).
These results suggest that culture of HIV-1 through
PBMC biases isolation of CCR5 only using viruses. To
further strengthen this observation, we isolated 16 viruses
from 11 more patients by PBMC coculture. The coreceptor
usage of these isolates is presented in Table 2. Only one
isolate, MM23-1, showed CCR3 use comparable to directly
cloned Envs. The majority (10 of 16) displayed very limited
CCR3 use (less than 10% of CCR5), supporting our
hypothesis. Indeed, the difference in the level of CCR3
use compared to CCR5 use between cloned Envs (median
46.5%) and the isolates generated by PBMC culture (median
6.0%) was a highly significant (Student's t test, P < 0.01).
Discussion
Our results show that efficient CCR3 use by HIV-1 (clade
B) is frequent in both early and chronic infection. Since
PBMC isolation favors the outgrowth of isolates that use
CCR5 exclusively, our results suggest that CCR3 use is
positively maintained in vivo and selected against in PBMC
culture. A possible positive selective force might be to
colonize specific compartments. For example, microglial cells
in the CNS express CCR3 that can mediate infection by
some HIV-1 isolates (He et al., 1997). However, microglialmean percentage of CCR3 use compared to the main coreceptor use of viruses
st two independent experiments and error bars the standard deviation between
es not alter their ability to use CCR3 for infection of NP2 cells.
Fig. 4. Analysis of CCR3 usage by low passage primary isolates. Comparison of CCR3 use by patient Env-chimeric viruses and limited passaged patient PBMC
isolates derived from similar time-points. In contrast to env cloning, virus isolation by PBMC coculture favors the growth of CCR5 only using viruses.
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Table 2












MM1 MM1–18 585 0.7 13 – c 5
MM14 MM14–1 40 – 17 – <1
MM14–9 519 – 90 – <1
MM23 MM23–1 15 9.5 12 – 80
MM23–12 316 1.7 195 – <1
MM24 MM24–1 26 2.5 10 – 25
MM24–10 464 0.2 1.1 – 14
MM25 MM25–2 31 0.5 630 – <1
MM26 MM26–2 62 1.9 95 – 2
MM26–11 384 0.4 6.7 – 6
MM27 MM27–1 28 3.1 120 – 3
MM27–11 585 0.6 10 – 6
MM28 MM28–1 6 0.3 3.2 – 9
MM28–10 503 0.1 0.6 – 16
MM33 MM33–1 26 0.8 4.0 – 20
MM34 MM34–2 25 0.5 3.0 – 17
MM34–3 32 3.7 54 – 7
MM35 MM35–1 37 12 1100 22 1
MM36 MM36–1 6 0.1 12 – <1
MM37 MM37–1 9 5.0 104 1.0 5
MM38 MM38–1 29 5.1 25 – 20
a Viruses obtained by co-culture of patient PBMC and healthy blood donor
PBMC, after a maximum of 28 days of culture.
b Time-point from which the patient PBMCwas derived, in days from onset of
symptoms characteristic of primary HIV-1 infection.
c –, <100 FFU/ml.
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use in vivo; we and others have shown that CCR3 using
Envs are also present in blood, lymph node, spleen and lung
tissues (Dittmar et al., 1997; Martin-Garcia et al., 2006;
Ohagen et al., 2003; Peters et al., 2004). Possible targets
include eosinophils, macrophages and T helper 2 cells,
which express CD4 and CCR3 either constitutively or
during inflammation (Sallusto et al., 1998). Furthermore,
CCR3 is up-regulated on blood monocytes in HIV-1 disease
(Price et al., 2001).
CCR3 could play a role in the pathogenesis of HIV-1
infection especially in patients with tuberculosis, malaria or
helminthic infections. In these diseases, T cell activation is
skewed toward the T helper 2 type (Lawn, 2004; Santucci et al.,
2004; Sarfo et al., 2004; Tkachuk et al., 2001), which express
high levels of CCR3 (Sallusto et al., 1998) and may be more
permissive to HIV (Maggi et al., 1994).
In summary, we have shown that the ability to
efficiently use CCR3 is a common trait of the replicating
HIV-1 quasi-species in vivo, and thus, CCR3 use could
have a role in viral pathogenesis. However, regardless of
the potential role of CCR3 use in vivo, our results show
that isolation of HIV-1 through PBMC does not accurately
reflect the virus population replicating in vivo. Indeed, the
outgrowing ‘primary isolates’ may even be relatively rare in
vivo. This finding could have implications on vaccine
designs that focus on Envs that are dedicated to CCR5 use.Materials and methods
Patient cohort
We analyzed the coreceptor usage of viruses from 18 HIV-1
infected men. Their likely route of exposure was sexual contact
with other men. Blood samples were obtained both at
seroconversion (6–84 days after onset of acute infection
symptoms) and about 1 or 2 year after infection (316–
833 days after onset of symptoms). Recent HIV-1 infection
was diagnosed by the detection of HIV-1 genomes (PBMC
proviral DNA or plasma RNA) in the presence, or absence, of
an evolving antibody profile that subsequently became fully
positive. All subjects declined antiretroviral therapy and
remained treatment naïve throughout the study.
The study protocol was approved by the Camden and
Islington NHS Trust Ethics Committee and written informed
consent obtained from all subjects.
Virus isolation by PBMC coculture
Viruses were isolated by coculture of patient PBMC and
phytohemagglutinin (PHA)-stimulated donor cells, following
standard techniques. Briefly, PBMC were isolated from
ethylenediaminetetraacetic acid (EDTA)-treated blood by
density gradient centrifugation and donor cells were incubated
with PHA (0.5 μg/ml) for 3 days prior to coculture. The cultures
were maintained in interleukin-2 (20 U/ml; Roche, Lewes, UK)
supplemented RPMI-1640 (Invitrogen, Paisley, UK) with 10%
(v/v) Foetal Calf Serum (FCS; Invitrogen, Paisley, UK) and
monitored for virus growth by p24 detection using the
Vironostika HIV Uni-Form II Ag/Ab microelisa system
(bioMérieux, Boxtel, The Netherlands). Fresh donor cells and
medium were added every 7 days. Viruses were harvested after
7–28 days of culture.
Amplification of gp120 and generation of chimeric molecular
clones
Viral envelopes from early infection time-points were
amplified from proviral DNA from patient PBMC, as
described previously (Aasa-Chapman et al., 2004). Brief-
ly, the gp120 was amplified using the primers 988L+ 5′-
GTAGCATTAGCGGCCGCAATAATAATAGCAATAG-3′,
943S+ 5′-CAA TAGYAGCATTAGTAGTAG-3′, 609RE−
5′-CCCATAGTGCTTCCGGCCGCTCCCAAG-3′ and 628L−
5′-TCATCTAGAGATTTATTACTCC-3′ for the first round.
For the nested polymerase chain reaction (PCR), primers 626L+
5′-GTGGGTCACCGTCTATTATGGG-3′ and 125Y− 5′-CAC-
CACGCGTCTCTTTGCCTTGGTGGG-3′ were used, which
contain BstEII and MluI sites (bold). The polymerase chain
reaction (PCR) conditions were 30 cycles of 92 °C for 45 s,
45 °C for 45 s and 68 °C for 210 s, finishing with a 7-min
elongation step at 68 °C. The same internal primers and PCR
conditions were also used for the subcloning of env from
previously characterized HIV-1 clones (HIV-1JRFL, HIV-1YU2,
HIV-189.6 and HIV-1NL4.3). Envelopes from chronic infection
495M.M.I. Aasa-Chapman et al. / Virology 351 (2006) 489–496time-points were amplified by nested reverse transcriptase
PCR (RT-PCR) from viral RNA, extracted from plasma
samples using the QIAamp Viral RNA Kit from Qiagen
(Crawley, UK). The extracted RNA was first DNAse I
treated (Promega, Southampton, UK) at 37 °C for 1 h and
purified using the QIAquick PCR Purification kit (Qiagen,
Crawley, UK). The same amplification protocol was used as
for amplification from PBMC DNA, with the exception that
the first amplification round was done using the Titan One
Tube RT-PCR Kit (Roche, Welwyn Garden City, UK) and
preceded by a reverse transcriptase step (50 °C for 30 min,
60 °C for 30 min).
The amplified env fragments were cloned into pGEM-T
Easy or pCR2.1-TOPO (both from Promega, Southampton,
UK) and subsequently transferred into pHxB2-MCS-Δ-env, by
digestion with BstEII and MluI. Plasmid pHxB2-MCS-Δ-env
allows incorporation of heterologous gp120 sequences from
amino acid 38 (seven amino acids after the signal peptide) to six
amino acids prior to the gp120/gp41 junction (McKeating et al.,
1996). The resulting molecular clones encode replication
competent viruses with gp41 derived from HIV-1HxB2.
Chimeric viruses were produced by transfection of 293T cells
using Fugene-6 (Roche, Welwyn Garden City, UK).
Plasmid DNA sequencing
The env gene of infectious virus clones were sequenced
using a cycle sequencing protocol using 3.2 pmol of primer and
500 ng of plasmid in accordance with the manufacturers
instructions (Big Dye Terminator Kit 3.1; Applied Biosystems,
Foster City, CA, USA). Both strands were sequenced using 5
primers each, to give an average 2- to 4-fold redundancy. The
sequences and their chromatograms were assembled into a
contig using Sequencher software to obtain consensus readings
(Gene Codes Corp.; Ann Arbor, Mich., USA). The env
sequences have been submitted to GenBank with accession
numbers: AY29500.1–02.1, AY295206.1, AY295211.1,
AY295214.1, AY295214.1, AY295219.1, AY295223.1,
AY295225.1–26.1, AY295233.1, AY295235.1, AY295237.1,
DQ425059-92.
Virus titration and coreceptor typing
Human glioma (NP2) and human mega-glioblastoma (U87)
cell lines, stably transfected with CD4 and CCR1, CCR2b,
CCR3, CCR5, CCR8, CXCR4 or APJ, were grown in
Dulbelcco's modified Eagle medium (DMEM; Invitrogen,
Paisley, UK) supplemented with 5% (v/v) FCS, 1 μg/ml
puromycin and 100 μg/ml G418. The cells were seeded at
2 × 104 cells/well in 48-well plates, to yield semiconfluent layers
the following day. Ten-fold serial dilutions of viral stocks were
incubated in triplicate on the cells for 2 h at 37 °C. The cells were
then washed once and cultured for 48 h. Infection was detected
by p24 immunostaining, as detailed elsewhere (Aasa-Chapman
et al., 2004). Briefly, fixed cells were incubated with mouse anti-
HIV-1 p24 monoclonal antibodies (ADP 365 and 266, NIBSC,
Potters Bar, UK; 1:40 dilution for 1 h) followed by a goat anti-mouse Ig antibody conjugated to β-galactosidase (Southern
Biotechnology Associates; Birmingham, Alabama, USA; at
2.5 μg/ml for 1 h). After incubation with X-Gal substrate at
37 °C, infected cells appear blue and focus-forming units (FFU)
are counted using light microscope. Each virus stock was titrated
at least three times on each cell line. The level (percentage) of
CCR3 use compared to the main coreceptor was calculated from
average ratios obtained from three or more parallel titrations on
CCR3 and CCR5 (or CXR4) expressing cells. Error bars
indicates standard deviations between experiments. The statis-
tical significance in differences in the level of CCR3 use between
study groups was tested by Student's t test.
Blocking experiments
NP2/CD4/CCR3 cells and NP2/CD4/CCR5 cells were
seeded as described above. One hour prior to infection with
∼300 FFU of virus, the culture medium was removed and
replaced with 100 μl/well of medium containing 0–1000 nM of
the CCR3 antagonist UCB35625 (Sabroe et al., 2000). Each
virus was plated in triplicate onto each dilution of UCB35625.
Inoculates were removed after 2 h and infection detected 48 h
later by p24 staining (as above).
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